Related Experiment Videos
Prenatal and postnatal treatment in cobalamin C defect
Martina Huemer1, Burkhard Simma, Brian Fowler
1Department of Pediatrics, Landeskrankenhaus, Feldkirch, Austria. martina.huemer@lkhf.at
The Journal of Pediatrics
|October 18, 2005
Summary
Prenatal treatment with hydroxycobalamin (OH-Cbl) did not prevent characteristic symptoms of cobalamin C defect in an infant. Despite treatment and normal development, the child exhibited disease-specific signs.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Cobalamin C defect is a severe inherited metabolic disorder.
- Early diagnosis and treatment are crucial for managing cobalamin C defect.
- Prenatal diagnosis and intervention are being explored for severe forms.
Observation:
- This study evaluated prenatal hydroxycobalamin (OH-Cbl) treatment in a pregnancy at risk for cobalamin C defect.
- Maternal methylmalonic aciduria was absent during the last trimester with prenatal OH-Cbl treatment.
- Postnatal treatment included OH-Cbl, carnitine, folate, betaine, and a protein-restricted diet.
Findings:
- Prenatal OH-Cbl treatment did not prevent the development of characteristic symptoms of cobalamin C defect.
- Odd long-chain fatty acids in cord blood erythrocytes did not reflect fetal methylmalonic aciduria.
- The child achieved normal developmental milestones but presented with nystagmus, retinopathy, and hypotonia.
Implications:
- This case highlights that even with comprehensive prenatal and postnatal treatment, severe cobalamin C defect can manifest with characteristic symptoms.
- Further research is needed to optimize prenatal and postnatal management strategies for cobalamin C defect.
- The findings underscore the complexity of managing inborn errors of metabolism and the need for ongoing monitoring.